| Not Yet Recruiting | Adoption of Audio Recording in the Outpatient Supportive Care Center NCT04871477 | M.D. Anderson Cancer Center | — |
| Withdrawn | STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Col NCT06626256 | City of Hope Medical Center | Phase 1 |
| Recruiting | Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in P NCT06364410 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Design and Testing of a Web-Based Tool for the Improvement of End-of-Life Planning in Patients With Advanced C NCT05564468 | Fred Hutchinson Cancer Center | N/A |
| Suspended | Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Trea NCT05554380 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumo NCT05564377 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcino NCT05472220 | Pamela Munster | Phase 1 |
| Recruiting | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Soli NCT05269381 | Mayo Clinic | Phase 1 / Phase 2 |
| Withdrawn | BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors NCT05010096 | M.D. Anderson Cancer Center | Phase 1 |
| Suspended | Assessment of Verbal Comprehension and Cognitive Processes in Patients Admitted to the Palliative and Supporti NCT05091632 | M.D. Anderson Cancer Center | — |
| Recruiting | Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors NCT04879121 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma NCT04387071 | University of Southern California | Phase 1 / Phase 2 |
| Completed | Distress Associated with Coronavirus Disease 2019 and Telehealth on Supportive Care Patients with Advanced Can NCT05058339 | M.D. Anderson Cancer Center | — |
| Recruiting | Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations NCT04550494 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Sol NCT04800627 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Integrative Palliative Care/Psycho-Oncology Telehealth Intervention in Patients With Advanced Cancer NCT04697524 | University of California, San Francisco | N/A |
| Recruiting | Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Sol NCT04771520 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | PLAN Intervention to Enhance Engagement of Latino Cancer Patients in Advanced Care Planning NCT04889144 | Fred Hutchinson Cancer Center | N/A |
| Withdrawn | Testing the Safety of CB-5339 in Patients With Cancer NCT04372641 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Me NCT04068194 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers NCT04082572 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial NCT03907475 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Ca NCT03868423 | Sameek Roychowdhury | Phase 2 |
| Active Not Recruiting | Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 NCT03284385 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors NCT03682289 | Rahul Aggarwal | Phase 2 |
| Active Not Recruiting | Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Ad NCT03583255 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-I NCT02321501 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medication NCT02595866 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types NCT06075524 | Mayo Clinic | — |
| Completed | Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer NCT01902173 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |